NewLimit

Following breakthrough results, we’re bringing longevity medicine to human trials. We’ve raised a $435M Series C led by @foundersfund to make it happen. Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it. https://t.co/YkPaGkS4bK

LATEST: ⚡️ Brian Armstrong's anti-aging biotech Newlimit raised $435M in a Series C, tripling its valuation to $3.1B, and plans to start human trials next year. https://t.co/GPmRm6UBMV